References of "Dresse, Marie-Françoise"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailEffect of N-acetylcysteine on pain in daily life in patients with sickle cell disease: a randomised clinical trial
Sins, JWR; Fijnvandraat, K; Rijneveld, AW et al

in British Journal of Haematology (2017)

Detailed reference viewed: 9 (0 ULiège)
Full Text
Peer Reviewed
See detailMetronomic treatments in Pediatric Neuro-Oncology, a new therapeutic alternative?
Fohn, Anaïs; Hoyoux, Claire; DRESSE, Marie-Françoise ULiege et al

in Tijdschrift van de Belgische Kinderarts = Journal du Pédiatre Belge (2017, March), 19(1), 88

Detailed reference viewed: 10 (0 ULiège)
Full Text
Peer Reviewed
See detailNewborn screening for sickle cell disease : 13 years at the CHR "La Citadelle", Liège
Sepulchre, Edith; Ketelslegers, Olivier; Minon, Jean-Marc et al

in Tijdschrift van de Belgische Kinderarts = Journal du Pédiatre Belge (2016, March), 18(1), 107

Detailed reference viewed: 23 (0 ULiège)
Full Text
See detailContraception hormonale chez l'adolescente avec thrombophilie biologique
Minon, Jean-Marc; Vasbien, Myriam; DRESSE, Marie-Françoise ULiege et al

in Belgian Journal of Paediatrics (2016), 18(2), 173-176

Venous thromboembolism among pill users is rare but is a serious complication. Women with inherited thrombophilia are at increased risk when taking combined oral contraceptives. It is also truth for the ... [more ▼]

Venous thromboembolism among pill users is rare but is a serious complication. Women with inherited thrombophilia are at increased risk when taking combined oral contraceptives. It is also truth for the contraceptive patch and vaginal ring. Hence, the adolescents with a know biological thrombophilia should not take htis type of hormonal conraception. However, some of these thrombophilia should not preclude use of estrogen containing contraception. Actually, if thrombophilia testing can be justified in asymptomtic patient at high risk, it is sometimes performed as screening in adolescent before estrogen-containnig contraception use ( non recommended). In these situations and considering the venous thrombosis as a multicausal disease, the choice of contraceptive methods is argued on the base of family history and other personnal risk factors of venous thrombosis. [less ▲]

Detailed reference viewed: 63 (0 ULiège)
Full Text
Peer Reviewed
See detailPurpura thrombocytopénique idiopathique...idiopathique, vraiment?
LONGTON, Julie ULiege; DRESSE, Marie-Françoise ULiege; Florkin, Benoît et al

in Tijdschrift van de Belgische Kinderarts = Journal du Pédiatre Belge (2016), 18(1), 112

Detailed reference viewed: 19 (1 ULiège)
Full Text
Peer Reviewed
See detailTumeurs rhabdoïdes néonatales : à propos de deux cas.
Carichon, T; FORGET, Patricia ULiege; Piette, Caroline ULiege et al

in Tijdschrift van de Belgische Kinderarts = Journal du Pédiatre Belge (2015), 17(1),

Detailed reference viewed: 22 (1 ULiège)
Full Text
Peer Reviewed
See detailPosterior Reversible Encephalopathy Syndrome in Pediatric Leukemia
Carichon, Tifenn ULiege; Piette, Caroline ULiege; Florkin, Benoît et al

in Tijdschrift van de Belgische Kinderarts = Journal du Pédiatre Belge (2015), 17(1), 48

Detailed reference viewed: 18 (1 ULiège)
Full Text
Peer Reviewed
See detailSplénomégalie palustre hyperimmune et drépanocytose. A propos d'un cas
Lefevre, Annabelle; Hoyoux, Marie; DRESSE, Marie-Françoise ULiege

in Tijdschrift van de Belgische Kinderarts = Journal du Pédiatre Belge (2015), 17(1),

Detailed reference viewed: 10 (0 ULiège)
Full Text
Peer Reviewed
See detailL'impact d'un programme régulier d'Erythrocytaphérèse sur les complications de la drépanocytose
DRESSE, Marie-Françoise ULiege; Hoyoux, Marie; Ketelslegers, Olivier et al

in Tijdschrift van de Belgische Kinderarts = Journal du Pédiatre Belge (2015), 17(1), 82

Detailed reference viewed: 21 (0 ULiège)
Full Text
Peer Reviewed
See detailDescription and Management of Accelerated Phase and Blast Crisis in 21 CML Pediatric Patients
Meyran, Deborah; Petit, Arnaud; Guilhot, Joelle et al

Poster (2015)

Philadelphia-positive chronic myelogenous leukemia (CML) is a rare disease in children and constitutes approximately 3-5% of all childhood leukemias. With tyrosine kinase inhibitors (TKI), the frequency ... [more ▼]

Philadelphia-positive chronic myelogenous leukemia (CML) is a rare disease in children and constitutes approximately 3-5% of all childhood leukemias. With tyrosine kinase inhibitors (TKI), the frequency of accelerated phase (AP) or blast crisis (BC) is remarkably reduced, estimated to 1% to 1.5% per year in adults compared with more than 20% per year in the pre-TKI era. But no data are available among children. Purpose: We described the characteristics, the treatment and the outcome of 21 children with CML, who evolved in accelerated phase and/or blast crisis under TKI. Results: From 2001 to april 2015, 415 European patients were enrolled in the CML pediatric database. Twenty-one patients (5.1%), in chronic phase (CP) treated by TKI, presented AP or BC. The median age of AP /BC cohort was 13.2 years (range: 4.5-16.9 years) with a sex ratio M/F at 2. At CML diagnosis, 15 patients (71%) had high risk Sokal Score with a median score of 1,4 (range: 0,16-2,4). All patients harbored t(9;22)(q34;q11) but one had a complex translocation t(1;9;22)(q12;q34;q11) and another one presented additional inv(3)(q21q26). Imatinib was the first line TKI for all patients. Before AP or BC, only five patients (24%) obtained a complete cytogenetic response (CCyR) and three achieved MMR. For incomplete molecular response or progression to accelerated phase, 8 patients (38%) were switched to dasatinib. Median duration of TKI before AP or BC was 11 months (range: 3 months-56.5 months). Six patients evolved to AP with a median interval of 8.7 months (range: 1 months-24 months), leading to blast crisis for 4 patients with a median time of 3.5 months (range: 0.3-5.4 months). Among the 2 patients remaining in AP, imatinib was increased for one and the other was switched for dasatinib, all before hematopoietic stem cells transplantation (HSCT). One patient died of post-transplant complication and the other one is still alive in complete molecular response without TKI. Nineteen patients presented BC, including 4 after AP. Thirteen patients (62%) presented ALL, five (24%) AML and one a bi phenotypic leukemia. Central nervous system (CNS) was involved for two patients with ALL, one isolated, one combined. At AP or BC, nine patients (43%) presented new additional cytogenetic abnormalities. Eighteen patients with BC were treated according to AML or ALL protocols, combined with second generation TKI for twelve patients. Only one patient underwent preparative regimen, without intensive chemotherapy before HSCT. Ten patients reached complete remission. Four patients died before HSCT, by progressive disease for 2 and by fatal infection for 2. Overall, 15 patients in BC were transplanted. Before HSCT, median molecular response was 0.2% (range: 0-29%) and only four patients had a complete molecular response. After transplant, seven patients received second generation TKI. Four patients died, including three related to transplant toxicity. Thirteen patients were alive, but one with ALL BC relapsed 26 months post-transplant and was waiting for second HSCT. With a median follow-up of 4.4 years, 4-year overall survival was 59% (66% for ALL BC versus 40% for AML BC). Conclusion: Incidence of AP/BC after imatinib for CP CML is at 5%, in the CML pediatric database. Despite second generation TKI, combined with HSCT, outcome remains poor. Post-transplant indication of TKI is heterogenic. Recommendations would be useful for practice. [less ▲]

Detailed reference viewed: 28 (1 ULiège)
Full Text
Peer Reviewed
See detailSchizencephaly associated with a severe prothrombotic syndrome caused by antithombin III deficiency
Daron, Aurore; DRESSE, Marie-Françoise ULiege; Hoyoux, Claire ULiege et al

in Tijdschrift van de Belgische Kinderarts = Journal du Pédiatre Belge (2015), 17(1), 109

Detailed reference viewed: 22 (1 ULiège)
Full Text
Peer Reviewed
See detailDécrochage de la courbe de périmètre crânien et si l’origine n'était pas neurologique
LONGTON, Julie ULiege; DRESSE, Marie-Françoise ULiege; Hoyoux, Marie et al

in Tijdschrift van de Belgische Kinderarts = Journal du Pédiatre Belge (2015), 17(1), 46

Detailed reference viewed: 15 (3 ULiège)
Full Text
Peer Reviewed
See detailUNE TUMEUR RARE DE LA FACE CHEZ UN NOURRISSON DE 6 MOIS
Fontaine, C; DEMEZ, Pierre ULiege; FORGET, Patricia ULiege et al

in Tijdschrift van de Belgische Kinderarts = Journal du Pédiatre Belge (2015), 17(1), 46

Detailed reference viewed: 29 (0 ULiège)
Full Text
Peer Reviewed
See detailLE CANCER DU TRES JEUNE ENFANT : EPIDEMIOLOGIE LIEGEOISE
Fontaine, C; RIGO, Vincent ULiege; FORGET, Patricia ULiege et al

in Tijdschrift van de Belgische Kinderarts = Journal du Pédiatre Belge (2015), 17(1), 47

Detailed reference viewed: 16 (1 ULiège)
Full Text
Peer Reviewed
See detailUTILISATION D'UNE FISTULE ARTERIO-VEINEUSE CHEZ DES PATIENTS DREPANOCYTAIRES SOUS ERYTHROCYTAPHERESE
Hoyoux, Marie; DRESSE, Marie-Françoise ULiege; Minon, Jean-Marc et al

in Tijdschrift van de Belgische Kinderarts = Journal du Pédiatre Belge (2015), 17(1), 49

Detailed reference viewed: 21 (0 ULiège)
Full Text
Peer Reviewed
See detailSurvival among children and adults with sickle cell disease in Belgium: Benefit from hydroxyurea treatment
Lê, Phu Quoc; Gulbis, Béatrice; Dedeken, Laurence et al

in Pediatric Blood & Cancer (2015), 62

Objective. To evaluate the survival of patients with sickle cell disease (SCD) recorded in the Belgian SCD Registry and to assess the impact of disease-modifying treatments (DMT). Method. The Registry ... [more ▼]

Objective. To evaluate the survival of patients with sickle cell disease (SCD) recorded in the Belgian SCD Registry and to assess the impact of disease-modifying treatments (DMT). Method. The Registry created in 2008 included patients of eight centers. All available data in 2008 were retrospectively encoded in the database. After 2008 and until 2012, all data were recorded prospectively for already registered patients as well as newly diagnosed subjects. Data were registered from neonatal screening or from diagnosis (first contact) until last follow-up or death. Data included diagnosis, demography, and outcome data. Results. We collected data from 469 patients over a 5,110 patient years (PY) follow-up period. The global mortality rate was low (0.25/100 PY), although 13 patients died (2.8%) and was similar between children, adolescents (10–18 years), and young adults (P¼0.76). Out of the cohort, 185 patients received hydroxyurea at last follow-up (median duration of treatment: 10.3 years), 90 underwent hematopoietic stem cell transplantation (HSCT), 24 were chronically transfused, and 170 had never had any DMT. Hydroxyurea showed significant benefit on patients outcome as reflected by a lower mortality rate compared to transplanted individuals or people without DMT (0.14, 0.36, and 0.38 per 100 PY, respectively) and by higher Kaplan–Meier estimates of 15 year survival (99.4%) compared to HSCT (93.8%; P¼0.01) or no DMT groups (95.4%; P¼0.04). Conclusion. SCD mortality in Belgium is low with no increase observed in young adults. Patients treated with hydroxyurea demonstrate a significant benefit in survival when compared to those withoutDMTor transplanted. [less ▲]

Detailed reference viewed: 60 (1 ULiège)
Full Text
Peer Reviewed
See detailOsteopetrosis mimicking juvenile myelomonocytic leukemia.
Hoyoux, Claire ULiege; DRESSE, Marie-Françoise ULiege; FORGET, Patricia ULiege et al

in Pediatrics International : Official Journal of the Japan Pediatric Society (2014)

Detailed reference viewed: 16 (0 ULiège)
Full Text
Peer Reviewed
See detailThrombose veineuse rénale : un cas didactique
Tribolet, Sophie ULiege; DRESSE, Marie-Françoise ULiege; Lombet, Jacques et al

in Journal du pédiatre Belge (2014)

On retiendra que, devant toute hématurie macroscopique accompagnée d’une thrombocytopénie, d’une masse abdominale et/ou d’une anurie, voire d’une hypertension artérielle chez un nouveau-né, le diagnostic ... [more ▼]

On retiendra que, devant toute hématurie macroscopique accompagnée d’une thrombocytopénie, d’une masse abdominale et/ou d’une anurie, voire d’une hypertension artérielle chez un nouveau-né, le diagnostic de thrombose veineuse rénale doit être évoqué. L’échographie Doppler rénale est l’examen de choix pour le confirmer. En l’absence de consensus thérapeutique, outre la surveillance et la correction éventuelle des troubles hydroélectrolytiques, une héparinothérapie pourrait être initiée afin d’éviter l’extension thrombotique. La fibrinolyse est à réserver aux cas exceptionnels d’atteinte bilatérale. Cette pathologie reste malheureusement grevée d’une morbidité importante, avec parfois une atrophie, une insuffisance rénale et une hypertension artérielle. [less ▲]

Detailed reference viewed: 35 (4 ULiège)
Full Text
Peer Reviewed
See detailCOMMENT J’EXPLORE ET TRAITE UNE THROMBOSE VEINEUSE RÉNALE NÉONATALE : à propos d’un cas
Tribolet, S.; DRESSE, Marie-Françoise ULiege; Lombet, J. et al

in Revue Médicale de Liège (2014), 69(4), 169-174

Neonatal renal vein thrombosis is a rare condition. The present case is rather unfrequent and particularly educative since it shows the complete diagnostic triad including hematuria, flank mass and ... [more ▼]

Neonatal renal vein thrombosis is a rare condition. The present case is rather unfrequent and particularly educative since it shows the complete diagnostic triad including hematuria, flank mass and thrombocytopenia. The diagnosis relies on the demonstration, by Doppler ultrasound, of an obstructed renal venous bed. The investigation is completed by a platelet count and the determination of the prothrombin time, of the activated partial thromboplastin time as well as of the concentration of fibrinogen. The screening also includes the search for a possible etiology, such as a deficiency in coagulation proteins, the presence of antiphospholipid antibodies or of a genetic mutation of one of the coagulation factors. Since there exist no evidence based guidelines for the management of the disease, we will discuss the diagnosis and treatment in relation with the published literature. [less ▲]

Detailed reference viewed: 47 (7 ULiège)
Full Text
Peer Reviewed
See detailMinimal residual disease quantification by PCR in childhood acute lymphoblastic leukemia
Van der Straeten, J.; De Moerloose, B.; DRESSE, Marie-Françoise ULiege et al

in Belgian Journal of Hematology (2014), 5

ln Belgium approximately 70 children are diagnosed with acute Iymphoblastic leukaemia annually. For these children, the monitoring of minimal residual disease has an important prognostic value. The level ... [more ▼]

ln Belgium approximately 70 children are diagnosed with acute Iymphoblastic leukaemia annually. For these children, the monitoring of minimal residual disease has an important prognostic value. The level of minimal residual disease during the first three months of therapy is used to recognise subgroups that differ substantially in outcome. Two techniques are used for minimal residual disease monitoring: the Genescan method and the allele specifie oligonucleotide polymerase chain reaction. The Genescan method is a less sensitive method (10-3) but is fast and less expensive. The allele specifie oligonucleotide polymerase chain reaction requires more time and budget but has a sensitivity of 10-4-10-5• Both techniques have proven their value in minimal residual disease monitoring in childhood acute Iymphoblastic leukaemia. [less ▲]

Detailed reference viewed: 32 (0 ULiège)